Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumoursGianluca Del Conte(IRCCS Ospedale San Raffaele), Luca Gianni(IRCCS Ospedale San Raffaele)British Journal of CancerJuly 15, 201410.1038/bjc.2014.345Cited by 103SaveCiteExport RISWatch citationsRelated PapersPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study|Annals of Oncology|2022|382Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer|Breast Cancer Research|2017|129